newsfilter
← Latest News
Business Wire·

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Personalis, Inc. (NASDAQ:PSNL) today announced an expansion and extension of its strategic collaboration with